Cue Biopharma Inc Dossier - Source-backed chat

Cue Biopharma Inc

CUENASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)2.01

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $25.25Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $183.4M

Enterprise Value $167M

Shares Outstanding 7.3M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Cue Biopharma is undergoing a strategic transformation under newly appointed CEO Shao-Lee Lin, pivoting its focus toward precision immunoengineering for autoimmune and allergic diseases. The licensing of CUE-221 (a Phase 2 anti-IgE antibody) and the advancement of CUE-401 (a bifunctional IL-2/TGF-beta fusion protein) provide high-potential clinical catalysts in the second half of 2026. While going concern risks remain, a recent $30 million private placement and a $7.5 million milestone payment from Boehringer Ingelheim significantly bolster near-term liquidity, making the stock an attractive high-risk, high-reward opportunity.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$115.00

Mean target$115.00

High · most bullish analyst$115.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The China Phase 2 CSU study for CUE-221 yields ambiguous or negative results, delaying or halting the planned global Phase 2b food allergy trial. Regulatory delays push the CUE-401 IND submission into 2027, and the company is forced to raise highly dilutive capital under going-concern pressure.

Base CaseCentral scenario

Cue Biopharma successfully submits the IND amendment for CUE-221 and the IND for CUE-401 in 2H 2026. Positive Phase 2 CSU data from the China study of CUE-221 triggers the initiation of a global Phase 2b trial in food allergy. The company manages its cash runway effectively through disciplined R&D spending and strategic collaborations.

Bull CaseUpside scenario

Cue Biopharma's bull case centers on its newly in-licensed Phase 2 anti-IgE antibody, CUE-221 (formerly Ascendant-221/UB-221), which targets the multi-billion-dollar allergy market dominated by Xolair. CUE-221 was designed by Dr. Tse Wen Chang, the original inventor of Xolair, and has demonstrated single-dose IgE suppression lasting over 12 weeks in Phase 1 trials, potentially allowing for quarterly dosing instead of Xolair's bi-weekly or monthly regimen. A clean active-comparator win in the upcoming Phase 2 chronic spontaneous urticaria (CSU) trial (expected in H2 2026) could trigger significant buyout interest, drawing parallels to GSK's $2.2 billion acquisition of RAPT Therapeutics for a comparable Phase 2 anti-IgE asset.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong leadership transition with the appointment of CEO Shao-Lee Lin, M.D., Ph.D., who has a proven track record of scaling biotech companies and driving regulatory approvals.
Differentiated precision immunoengineering platform (Immuno-STAT) targeting functional cures for immunological disorders without broad immune suppression.
Near-term clinical catalysts in 2H 2026, including Phase 2 CSU data for CUE-221 and IND submissions for both CUE-221 and CUE-401.
Validated platform through high-profile collaborations, including a licensing deal with Boehringer Ingelheim for CUE-501.

Key Investment Risks

Substantial doubt about the company's ability to continue as a going concern, requiring continuous access to capital markets or strategic partnerships.
Clinical development and regulatory execution risks inherent in early-to-mid-stage biopharmaceutical assets.
Potential dilution from the exercise of warrants issued in connection with the May 2026 private placement and licensing transactions.

Thesis Invalidation Triggers

Failure or significant delay in submitting INDs for CUE-221 or CUE-401 in the second half of 2026.
Negative or safety-compromised clinical data from the ongoing Phase 2 CSU study of CUE-221 in China.
Inability to secure additional non-dilutive funding or strategic partnerships, leading to severe liquidity constraints.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.